Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis
1 other identifier
observational
100
1 country
1
Brief Summary
Dermatophytosis is a common superficial infection of the skin, hair, or nails caused by dermatophyte, it is colloquially known as ringworm or tinea infection and affects an estimated one in five people in their lifetime
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2026
CompletedFirst Posted
Study publicly available on registry
September 1, 2026
CompletedStudy Start
First participant enrolled
October 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 20, 2027
September 1, 2026
August 1, 2026
2 months
August 27, 2026
August 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Evaluate the clinical and dermoscopic features of resistant dermatophytosis of non-glabrous skin.
October 2026- March 2027
Assess of the mycological features of resistant dermatophytosis of non-glabrous skin.
January 2027- April 2027
Determine the in vitro susceptibility profile of dermatophyte isolates.
April 2027 to June 2027
Molecular identification of different species of dermatophytes using PCR.
June 2027 to August 2027
Study Arms (1)
Clinically diagnosed resistant dermatophytosis (e.g., tinea corporis, cruris,…), resistant dermatop
Interventions
Clinicians typically will use a scalpel or curette to scrape the lesion's edge, particularly the most recent lesion where fungal elements are most likely to be found . Specimens will be collected after proper skin cleansing with alcohol 70 % a and sealed in sterile dry Petri dishes (Gold and Lockhart, 2025). Samples will be labeled with the patient's name, age, sex, date of collection, and site of infection and subsequently brought to the laboratory for mycological examination . The samples collected will be screened for the presence of fungal elements using a 10% KOH with 40% Dimethyle sulphoxide (DMSO) mount mixed in equal proportion
After a direct microscopic examination, skin scraping specimens will be inoculated in a Petri dish: containing sabrouds Dextrose Agar added to it (chloramphenicol ) acts as a broad spectrum antibiotic, which inhibits a wide range of gram-positive and gram-negative bacteria) and cycloheximide (to inhibit saprophytic fungi) and other Petri dish containing Dermasel agar base, supplemented with chloramphenicol and cycloheximide. Cultures will be incubated aerobically at room temperature (25°C) for up to 4 weeks. Positive cultures will be examined both macroscopically (color of the surface and reverse, topography, and texture) and microscopically (after staining of growth colony with lactophenol cotton blue stain or methylene blue stain) to determine two types of conidia for species identification. In the absence of any growth after 4 weeks, the culture will be considered negative
Agar Based Disc Diffusion (ABDD) antifungal susceptibility testing will be performed using eight antifungal agents: Clotrimazole, Miconazole, Fluconazole, Ketoconazole, Terbinafine, Voriconazole, Itraconazole and Griseofulvin on Mueller-Hinton medium. When growth occurs, the size of the zones of inhibition around the disks will be measured and recorded. Criteria of susceptibility and resistance of antifungal agents will be measured according to clinical and laboratory standards institutes (CLSI
1. Extraction of fungal nucleic acid: will be done using commercial kits. 2. Amplification and detection of different species using species- specific primers by conventional PCR.
Eligibility Criteria
It's a cross sectional study will be conducted on patients attending the outpatient clinic of Dermatology, Venereology, and Andrology department in Sohag University Hospital over a period of 12 months between August, 2026 to July, 2027. Setting : Outpatient clinic of Dermatology, Venereology, and Andrology department in Sohag University Hospital.
You may qualify if:
- Clinically diagnosed resistant dermatophytosis (e.g., tinea corporis, cruris,…), resistant dermatophytosis (no cure despite adequate antifungals), recurrent (reoccurrence \<6 weeks post treatment) or disease duration \>6-12 months (Gharib et al., 2024) . 2. Age \>18 years, both sex.
You may not qualify if:
- Pregnant or lactating women will be routinely excluded due to potential risks of antifungal medication.
- Patients with recent systemic antifungal use (often within 1 month) or topical antifungals (within 2 weeks).
- Chronic systemic diseases (e.g., diabetes mellitus, hepatic or renal impairment).
- Patients receiving immunosuppressive drugs (systemic corticosteroids or other immunomodulatory drugs).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag university, Faculty of medicine
Sohag, Egypt
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Marwa Ragab Yassen, Demonstrator
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Demonstrator of dematology and venerology
Study Record Dates
First Submitted
August 27, 2026
First Posted
September 1, 2026
Study Start
October 1, 2026
Primary Completion (Estimated)
November 20, 2026
Study Completion (Estimated)
August 20, 2027
Last Updated
September 1, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share